Clinical Trial Update: Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating sunitinib malate for iodine-refractory recurrent or metastatic thyroid cancer has completed enrollment and posted results in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Thyroid Cancer
• Medullary Thyroid Carcinoma
• Papillary Thyroid Cancer
• Thyroid Cancer

Drugs mentioned

• Sutent (sunitinib)

Snippet

Sponsor: University of Washington | Conditions: Recurrent Thyroid Cancer, Stage IVA Follicular Thyroid Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-04-25